492 related articles for article (PubMed ID: 30862658)
1. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus.
Halden TAS; Kvitne KE; Midtvedt K; Rajakumar L; Robertsen I; Brox J; Bollerslev J; Hartmann A; Åsberg A; Jenssen T
Diabetes Care; 2019 Jun; 42(6):1067-1074. PubMed ID: 30862658
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
[TBL] [Abstract][Full Text] [Related]
3. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
[TBL] [Abstract][Full Text] [Related]
4. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
[TBL] [Abstract][Full Text] [Related]
6. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Häring HU; Merker L; Seewaldt-Becker E; Weimer M; Meinicke T; Broedl UC; Woerle HJ;
Diabetes Care; 2014 Jun; 37(6):1650-9. PubMed ID: 24722494
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Barnett AH; Mithal A; Manassie J; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Lancet Diabetes Endocrinol; 2014 May; 2(5):369-84. PubMed ID: 24795251
[TBL] [Abstract][Full Text] [Related]
9. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS
Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Roden M; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2015 Dec; 14():154. PubMed ID: 26701110
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
12. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Ferrannini E; Seman L; Seewaldt-Becker E; Hantel S; Pinnetti S; Woerle HJ
Diabetes Obes Metab; 2013 Aug; 15(8):721-8. PubMed ID: 23398530
[TBL] [Abstract][Full Text] [Related]
13. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
[TBL] [Abstract][Full Text] [Related]
14. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients.
Babar M; Hussain M; Ahmad M; Akhtar L
J Ayub Med Coll Abbottabad; 2021; 33(2):188-191. PubMed ID: 34137526
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
Zinman B; Inzucchi SE; Wanner C; Hehnke U; George JT; Johansen OE; Fitchett D;
Diabetologia; 2018 Jul; 61(7):1522-1527. PubMed ID: 29713728
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
18. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Ridderstråle M; Andersen KR; Zeller C; Kim G; Woerle HJ; Broedl UC;
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):691-700. PubMed ID: 24948511
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
Dig Dis Sci; 2020 Feb; 65(2):623-631. PubMed ID: 30684076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
